Chembio Diagnostics - 15 Year Stock Price History | CEMI

Historical daily share price chart and data for Chembio Diagnostics since 2004 adjusted for splits. The latest closing stock price for Chembio Diagnostics as of July 22, 2019 is 6.09.
  • The all-time high Chembio Diagnostics stock price is 16.00, which is 162.7% above the current share price.
  • The Chembio Diagnostics 52-week high stock price is 11.50, which is 88.8% above the current share price.
  • The Chembio Diagnostics 52-week low stock price is 4.95, which is 18.7% below the current share price.
  • The average Chembio Diagnostics stock price for the last 52 weeks is 7.53.
Chembio Diagnostics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2019 6.5436 5.6600 7.8500 5.3200 6.0900 7.60%
2018 8.7806 8.1000 11.5000 4.9500 5.6600 -30.98%
2017 6.2502 6.6500 8.3500 5.2500 8.2000 20.59%
2016 6.7890 5.2100 9.1200 4.2800 6.8000 27.58%
2015 4.5294 3.8700 5.3400 3.5600 5.3300 36.32%
2014 3.5915 3.4000 4.7300 2.8700 3.9100 16.02%
2013 4.4190 4.7501 5.7100 3.2900 3.3700 -28.75%
2012 4.3034 3.4400 5.2599 3.2800 4.7300 40.77%
2011 3.4753 3.2800 4.5600 2.4800 3.3600 -1.18%
2010 2.1713 2.1600 3.6400 1.5200 3.4000 51.79%
2009 1.3250 0.8800 2.9600 0.6400 2.2400 154.55%
2008 1.3837 1.9200 2.4000 0.6000 0.8800 -59.26%
2007 4.6029 6.1600 7.2000 2.1600 2.1600 -67.47%
2006 5.8140 3.0400 8.2400 2.6400 6.6400 137.14%
2005 4.8378 5.7600 6.5600 2.4400 2.8000 -51.39%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.103B $0.033B
CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $154.348B 29.07
Medtronic (MDT) Ireland $135.189B 19.31
Stryker (SYK) United States $77.613B 27.70
Boston Scientific (BSX) United States $58.755B 28.17
Baxter (BAX) United States $42.395B 26.72
EssilorLuxottica Societe Anonyme (ESLOY) France $29.186B 0.00
Coloplast (CLPBY) Denmark $25.855B 41.28
Lonza Group Ag (LZAGY) Switzerland $25.565B 0.00
Zimmer Biomet Holdings (ZBH) United States $25.282B 16.24
Terumo (TRUMY) Japan $22.330B 25.68
Smith & Nephew SNATS (SNN) United Kingdom $18.881B 0.00
ResMed (RMD) United States $17.703B 33.83
Sunny Optical Technology (SNPTF) China $12.345B 0.00
Canopy Growth (CGC) Canada $12.272B 0.00
Bio-Rad Laboratories (BIO) United States $9.392B 49.79
William Demant Holdings (WILYY) Denmark $7.263B 0.00
Insulet (PODD) United States $7.231B 526.83
Hill-Rom Holdings (HRC) United States $7.018B 21.27
Perrigo (PRGO) Ireland $7.012B 11.85
Aurora Cannabis (ACB) Canada $6.936B 68.40
GN STORE NORD (GNNDY) Denmark $6.409B 32.73
Haemonetics (HAE) United States $6.251B 51.03
ICU Medical (ICUI) United States $5.188B 30.95
GW Pharmaceuticals (GWPH) United Kingdom $4.991B 0.00
Neogen (NEOG) United States $3.334B 54.21
NuVasive (NUVA) United States $3.016B 24.63
Hutchison China MediTech (HCM) China $2.777B 0.00
Agios Pharmaceuticals (AGIO) United States $2.746B 0.00
National Vision Holdings (EYE) United States $2.480B 52.83
Quidel (QDEL) United States $2.268B 23.54
Aphria (APHA) $1.604B 0.00
Cardiovascular Systems (CSII) United States $1.544B 886.40
Phibro Animal Health (PAHC) United States $1.216B 18.22
AtriCure (ATRC) United States $1.203B 0.00
VAREX IMAGING (VREX) United States $1.174B 24.93
NanoString Technologies (NSTG) United States $1.114B 0.00
Lantheus Holdings (LNTH) United States $1.097B 29.13
PetIQ (PETQ) United States $1.015B 24.66
Quanterix (QTRX) United States $0.779B 0.00
Cerus (CERS) United States $0.761B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.750B 21.03
Omeros (OMER) United States $0.719B 0.00
MacroGenics (MGNX) United States $0.717B 0.00
TG Therapeutics (TGTX) United States $0.681B 0.00
LeMaitre Vascular (LMAT) United States $0.598B 28.97
OraSure Technologies (OSUR) United States $0.530B 24.40
Surmodics (SRDX) United States $0.527B 76.59
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.499B 0.00
Meridian Bioscience (VIVO) United States $0.492B 15.04
BioLife Solutions (BLFS) United States $0.330B 103.12
Utah Medical Products (UTMD) United States $0.321B 22.20
Vapotherm (VAPO) United States $0.320B 0.00
Zynex (ZYXI) United States $0.251B 25.77
Cytosorbents (CTSO) United States $0.242B 0.00
Bovie Medical (APYX) United States $0.214B 0.00
Chimerix (CMRX) United States $0.188B 0.00
Rockwell Medical (RMTI) United States $0.174B 0.00
United Health Products (UEEC) United States $0.170B 0.00
Owens & Minor (OMI) United States $0.166B 3.52
Fonar (FONR) United States $0.142B 7.49
Female Health (VERU) United States $0.134B 0.00
United-Guardian (UG) United States $0.092B 20.16
Surface Oncology (SURF) United States $0.076B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.067B 0.00
Trinity Biotech (TRIB) Ireland $0.053B 18.33
ImmuCell (ICCC) United States $0.044B 0.00
Senestech (SNES) United States $0.038B 0.00
GUARDION HEALTH (GHSI) United States $0.037B 0.00
Capricor Therapeutics (CAPR) United States $0.020B 0.00
Valeritas Holdings (VLRX) United States $0.014B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.011B 0.00
Akers Biosciences Inc (AKER) United States $0.005B 0.00
NeuroMetrix (NURO) United States $0.004B 0.00